Biotech Executive Elizabeth Cormier-May appointed new CEO for women's health startup Mammogen

Biotech Executive Elizabeth Cormier-May appointed new CEO for women's health startup Mammogen

Published: 05-02-2021 10:01:34 | By: Pie Kamau | hits: 2245 | Tags:

Mammogen, Inc., a women's health startup born at the intersection of data, technology and science, and Bench International, a leading global executive search firm, jointly announce the appointment of Elizabeth Cormier-May as Chief Executive Officer and member of the board of directors of Mammogen. She will begin her new role on March 1st, 2021.  

In her new role, Cormier-May will lead efforts to develop, validate and commercialize the company's flagship liquid biopsy program for breast cancer, while working to position Mammogen as a global leader in women's health. The company has developed a proprietary methodology for early cancer detection using novel messenger RNA (mRNA) biomarkers, which has shown statistical significance towards providing measurable improvement upon current standards of care.

"When women think of their physical, mental and emotional health, I want Mammogen to be the first, second, and third thing that comes to mind," said Ms. Cormier-May. "Mammogen is working to detect earlier, diagnose easier, treat better, and to support all women throughout the life-long battle that comes with survivorship. Providing end-to-end care is good, but we think an end-to-never-end community is better. Mammogen's technology will provide regular and reliable screening and diagnostic tools for tens of millions of women who are grossly underserved by current standards of care. I am extremely excited to build off of Mammogen's strong scientific foundation and speed this innovation to market, so that we can get more women screened earlier and arm clinicians with actionable insights about their patients."

Mammogen's core technology is a non-invasive screening solution intended for all women, but particularly for the under-40 population who aren't eligible for annual mammography and the 55+ population who are only recommended for mammography every other year.

Ms. Cormier-May brings vast experience within medicinal chemistry, genetics, and both companion and molecular diagnostics while working with companies including Novartis Pharmaceuticals, Myriad Genetics, Qiagen, and Predictive Biosciences. Elizabeth built her career launching and selling diagnostic tests into the women's health, oncology and urology markets. During her tenure as Head of Commercial Operations at Exosome Dx (acquired by Bio-Techne), Elizabeth was responsible for building the infrastructure and defining the launch of the company's flagship diagnostic, ExoDx Prostate(IntelliScore).

Marty Keiser, Founder and Chairman, Mammogen: "I am humbled by the fact that of all the opportunities in this space, Elizabeth chose Mammogen. "Denise (DeeDee) DeMan, the founder and CEO of Bench International, immediately connected with my passion for improving women's health and my vision to build Mammogen as a women-led organization. DeeDee not only brought us a top CEO, but she has also joined our board of directors, bringing extensive experience and connections in the life science community that will continue to add value at every stage of growth for Mammogen."

Mammogen is one of three joint venture companies established between IV BioHoldings (IVBH), a bio innovation studio founded by Keiser, and leading healthcare analytics provider, Liquid Biosciences. "When Marty first told me of his plans to apply his unique approach to venture creation to women's health, including finding ways to offer underserved women access to innovative technologies, it was obvious that people would be one of his greatest assets," said Ms. DeMan. "When you combine Elizabeth's experience in liquid biopsies and early-stage diagnostics, her track record in unlocking value for patients, payers and stakeholders, and her courageous and ambitious spirit, there is no question that we found the perfect person to build Mammogen into an industry leader in women's health."

www.mammogen.bio